Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 6/20 | 0.41 |
| ▸ | HTR6 | P50406 | 7/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798945 | 0.90 | BRD4 (0.44) | PTPN11BRD4HTR6PDPK1LRRK2 | |
| SCHEMBL13745782 | 0.86 | PTPN11 (0.43) | PTPN11BRD4HTR6PDPK1AURKA | |
| SCHEMBL13746221 | 0.84 | BRD4 (0.44) | PTPN11BRD4HTR6PDPK1AURKA | |
| SCHEMBL13746014 | 0.84 | PTPN11 (0.45) | PTPN11BRD4HTR6PDPK1 | |
| SCHEMBL8321770 | 0.83 | BRD4 (0.41) | PTPN11BRD4HTR6PDPK1 | |
| SCHEMBL13745663 | 0.82 | BRD4 (0.41) | PTPN11BRD4HTR6PDPK1 | |
| SCHEMBL13745570 | 0.81 | PTPN11 (0.44) | PTPN11BRD4HTR6PDPK1AURKA | |
| SCHEMBL13745575 | 0.81 | PTPN11 (0.42) | PTPN11BRD4HTR6PDPK1AURKA | |
| SCHEMBL13745675 | 0.81 | PTPN11 (0.45) | PTPN11BRD4HTR6PDPK1AURKA | |
| SCHEMBL13745784 | 0.81 | PTPN11 (0.45) | PTPN11BRD4HTR6PDPK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | PTPN11 1694/4885BRD4 1339/4885HTR6 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.